sub:assertion {
d:DB00257 dv:ddi-interactor-in dr:DB00257_DB01394 .
d:DB01394 dv:ddi-interactor-in dr:DB00257_DB01394 .
dr:DB00257_DB01394 dct:identifier "drugbank_resource:DB00257_DB01394" ;
dct:title "DDI between Clotrimazole and Colchicine - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Clotrimazole and Colchicine - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function. [drugbank_resource:DB00257_DB01394]"@en .
}